Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685126 · ClinicalTrials.gov registry record · Phase 3
Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)
A Phase 3 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 3
- Development phase
- 117
- Enrollment target
NCT00685126 is a Phase 3 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 117 participants.
The verdict
NCT00685126, a Phase 3 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 117 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy of two dose levels of levalbuterol compared with one dose level of racemic albuterol in pediatric subjects aged birth to 48 months old.
Interventions
- DRUG Levalbuterol HCl Inhalation Solution
- DRUG Albuterol HCl Inhalation Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 117 participants |
| Start Date | 2001-02 |
| Est. Completion | 2002-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685126
The ClinicalTrials.gov registry entry for NCT00685126 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 117 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Levalbuterol HCl Inhalation Solution is the first listed.
NCT00685126 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685126 about?
NCT00685126 is a clinical study titled "Study of Levalbuterol and Racemic Albuterol in Pediatric Subjects With Reactive Airways Disease (RAD)". The purpose of this study is to compare the efficacy of two dose levels of levalbuterol compared with one dose level of racemic albuterol in pediatric subjects aged birth to 48 months old.
What is the current status of trial NCT00685126?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 117 participants. The study started on 2001-02. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00685126?
The interventions under investigation include: Levalbuterol HCl Inhalation Solution (DRUG), Albuterol HCl Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT00685126?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.